GENTAMICIN TEVA 80 MG2 ML Israel - English - Ministry of Health

gentamicin teva 80 mg2 ml

teva israel ltd - gentamicin as sulfate - solution for injection - gentamicin as sulfate 40 mg / 1 ml - gentamicin - gentamicin is indicated in bacteremia, urinary tract infections, endocarditis, chest infections and other serious systemic infections due to confirmed or expected bacteria that are susceptible to gentamicin, in adults and children, including neonates.

Respilief 100 mg per mL Solution For Injection (IM) Philippines - English - FDA (Food And Drug Administration)

respilief 100 mg per ml solution for injection (im)

chemvet products, inc. - gentamicin ( as sulfate) (vet.) - solution for injection (im) - 100 mg per ml

GENTAMICIN PANPHARMA 80 MG2 ML Israel - English - Ministry of Health

gentamicin panpharma 80 mg2 ml

pharmalogic ltd - gentamicin as sulfate - solution for injection - gentamicin as sulfate 80 mg / 2 ml - gentamicin - gentamicin is indicated in bacteremia, urinary tract infections, endocarditis, chest infections and other serious systemic infections due to confirmed or expected bacteria that are susceptible to gentamicin, in adults and children, including neonates.

GENTAMICIN B. BRAUN 3 MGML Israel - English - Ministry of Health

gentamicin b. braun 3 mgml

lapidot medical import and marketing ltd - gentamicin as sulfate - solution for infusion - gentamicin as sulfate 0.3 g / 100 ml - gentamicin - gentamicin - treatment of serious infections caused by susceptible microorganisms

B. BRAUN GENTAMICIN gentamicin (as sulfate) 80 mg/80 mL injection, intravenous infusion, bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 80 mg/80 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 1.39 mg/ml (equivalent: gentamicin, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

B. BRAUN GENTAMICIN gentamicin (as sulfate) 240 mg/80 mL injection, intravenous infusion, bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 240 mg/80 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

B. BRAUN GENTAMICIN gentamicin (as sulfate) 360 mg/120 mL injection, intravenous infusion, bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 360 mg/120 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

GENTAMICIN INJECTION USP SOLUTION Canada - English - Health Canada

gentamicin injection usp solution

hikma canada limited - gentamicin (gentamicin sulfate) - solution - 40mg - gentamicin (gentamicin sulfate) 40mg - aminoglycosides

GENTAMICIN INJECTION USP SOLUTION Canada - English - Health Canada

gentamicin injection usp solution

hikma canada limited - gentamicin (gentamicin sulfate) - solution - 10mg - gentamicin (gentamicin sulfate) 10mg - aminoglycosides

GENTAMICIN(E) 120MG LIQ IV 1.2MG/ML SOLUTION Canada - English - Health Canada

gentamicin(e) 120mg liq iv 1.2mg/ml solution

baxter corporation - gentamicin (gentamicin sulfate) - solution - 1.2mg - gentamicin (gentamicin sulfate) 1.2mg - aminoglycosides